Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0FRZQW
ADC Name	B12-PEG-G5-DOX
Synonyms	B12-PEG-G5 DOX Click to Show/Hide
Organization	Abion, Inc.
Drug Status	Investigative
Indication	In total 1 Indication(s) Ovarian cancer [ICD11:2C73] Investigative
Drug-to-Antibody Ratio	22
	3D MOL	2D MOL
Antibody Name	B12		Antibody Info
Antigen Name	Envelope glycoprotein gp160 (env)		Antigen Info
Payload Name	Cis-aconityl-doxorubicin		Payload Info
Therapeutic Target	DNA topoisomerase 2-alpha (TOP2A)		Target Info
Linker Name	B12-PEG-G5-DOX linker
Conjugate Type	Random conjugation through reduced heavy-chain cysteines.

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 56.39	%	CVCL_0465	Ovarian serous adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 56.39% (Day 84)
Method Description	The OVCAR-3 ovarian cancer cell line was mixed with matrigel and injected subcutaneously into Athymic nude immunodeficient mouse to observe tumor growth. After 77 days of tumor growth, treatment with the antibody (B12 antibody) and B12-Dendrimer Conjugates was initiated Nine doses were administered intraperitoneally three times a week.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells	CVCL_0465

References

Ref 1	Immune conjugate having dendron conjugated to antibody and use thereof.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.